Membranoproliferative nephritis has no effective treatment and cannot be cured. Early use of combination therapy can improve or stabilize renal function to a certain extent and improve the survival rate. Membranoproliferative nephritis, also known as mesangial capillary glomerulonephritis, is characterized by thickening of the glomerular basement membrane, capillary hyperplasia and dilatation of the mesangial stroma. It is mainly seen in children and adolescents, and its main manifestations include hematuria, proteinuria, hypertension, and renal function impairment. There is no effective treatment for primary membranoproliferative nephritis, and the treatment is mainly based on glucocorticoids, antiplatelet and anticoagulant therapy (aspirin, disulfiram, etc.), cytotoxic drugs and other immunosuppressive drugs (mertiomacrophenol ester, cyclosporine), etc. The prognosis of this disease is poor, and the disease is mainly characterized by hematuria, proteinuria, hypertension, and renal function impairment. The disease has a poor prognosis and continues to progress. If you suffer from membranoproliferative nephritis, it is recommended that you consult a doctor in a timely manner and use medication under the guidance of a professional physician to control the development of the disease and prevent it from deteriorating.